All GLG News Analyses Filed Under: Endocrinology

Aclasta, an IV bisphosponate known generically as zoledronic acid, seems to do one thing consistently: it has an uncanny knack for showing an absolute risk reduction of about 1-2% in whatever endpoint is being measured, and against whatever control it faces head-to-head.  It has been shown to have...

Reclast will make life much easier for patients with osteoporosis. This study strenghtens this oncept. The ig problem is coverage. Ther is still a lag between the data and payors. Once this is resolved use of Reclast will be the way to go.

The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.

Postmenopausal osteoporosis is a real problem for a huge number of the older aged patients, and the population is aging. In daily orthopaedic praxis, I see a lot of osteoporosis related fractures of the wrist, the hip, and the vertebral column. Just yesterday, I operated a pseudarthrosis in the femoral...

The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...

Merck's endocannabinoid inverse agonist (CB1R )recently completed a 52 wk trial in which 2000 subjects were randomized to placebo, 2, 4, or 6 mg of taranabant.  Before the trial ended, the 6 mg dosed subjects had to be rerandomized to placebo or 4 mg due to toxicity.  The...

the first issue for me to wonder about is the mechanism of action, and what type of drug is it?  Is it a biological or bisphosphonate?  What are potential side effects?  Long or short term.  What are the contra-indications?  Can it be used in children with bone metabolism disorders,...

Osteoporosis treatment is becoming highly competitive.  So how competitive is Denosumab's profile?

Although the concept is exciting--an inverse agonist at the cannabinoid-1 (CB-1) receptor to reduce appetite, this medicine has a lot of bad press from rimonabant to overcome.  The major problem with rimonabant was psychopathological reactions in patients.  We do not yet know whether this...

We indeed better meds for the treatment of osteoporosis. If it indeed shows fracture reduction besides increased bone density with few side effects it will have a place in the market.The other issue, however, will be the cost and which insurers will cover it now that we have generic fosomax.